AstraZeneca (LON:AZN) Price Target Raised to GBX 74

AstraZeneca (LON:AZN) had its price target boosted by stock analysts at Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a note issued to investors on Tuesday, Digital Look reports. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective points to a potential downside of 99.39% from the stock’s current price.

Several other research firms also recently issued reports on AZN. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, May 28th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 21st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($139.13) price objective on shares of AstraZeneca in a research report on Tuesday, June 18th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Tuesday, June 4th. Finally, Barclays reaffirmed an “overweight” rating and set a £125 ($158.11) price target on shares of AstraZeneca in a research note on Monday, April 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of £105.53 ($133.49).

AstraZeneca Price Performance

LON AZN traded down GBX 220 ($2.78) during mid-day trading on Tuesday, hitting £120.84 ($152.85). The stock had a trading volume of 9,346,402 shares, compared to its average volume of 2,235,114. The company has a 50 day simple moving average of £122.31 and a 200 day simple moving average of £110.81. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51. The company has a market cap of £187.30 billion, a price-to-earnings ratio of 3,873.08, a P/E/G ratio of 0.97 and a beta of 0.16. AstraZeneca has a 52-week low of GBX 9,461 ($119.67) and a 52-week high of £127.04 ($160.69).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.